URMC / Research / Health Research /Clinical Trials / Study Details

Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

Research Question:
Does the drug Seralutinib improve the exercise capacity of people with Pulmonary Arterial Hypertension (PAH)?

Basic Study Information

Purpose:
Seralutinib is an inhaled medication for PAH. Participants with PAH age 18-75 and a BMI of 17-40 may be eligible to participate. Participants will be randomized to either placebo or drug. The duration of the study is up to a maximum of 48 weeks.

Location: University of Rochester Medical Center
Study Reference #: STUDY00008886

Lead Researcher (Principal Investigator)

Lead Researcher: R White, III

Study Contact Information

Study Coordinator: GB002, Inc.
Email: ClinicalTrials@gossamerbio.com

Additional Study Details

Contact This Study

First Name *

This field is required

Middle Name

Last Name *

This field is required

Phone Number

I agree to be contacted by The University of Rochester Medical Center regarding participation in this study. *

You must agree to be contacted to continue.

Please call me during the day.

Please call me during the evening.

Message

Return to Search

Research

UR Health Research